Metabolic & GLP-1

1. Metabolic & GLP-1well supported · human dataAdded 29 August 2026

   Weight-loss jabs shed muscle too: semaglutide users lost 5.44 kg of lean mass

   Pooled results from seven trials in 821 people with obesity show GLP-1 drugs at weight-loss doses reduced absolute lean mass by an average of 1.74 kg, with semaglutide showing the biggest loss at 5.44 kg. Even so, lean mass as a proportion of total body weight improved by 1.81%, since total weight fell faster still.

   ⚠What it shows: Reasonably solid on the headline numbers: results pooled from seven trials covering 821 people with obesity, all tested against placebo. The trials disagreed a lot on the size of the muscle loss, and none compared the drugs against diet and exercise plans, so it cannot say how much muscle a person who trains would keep.Meta-analysis · Int J Obes (Lond)

   Full breakdown →Sarcopenia explained →Protein Intake Calculator →Effect of GLP-1 receptor agonists at doses for obesity management on muscle health: systematic review and meta-analysis of randomized controlled trials (RCTs). Int J Obes (Lond) 2026
2. Metabolic & GLP-1well supported · human dataAdded 27 August 2026

   Three light lifting sessions a week lowered blood sugar in type 2 diabetes

   Pooling 10 randomised trials with 633 overweight or obese adults with type 2 diabetes, resistance training improved HbA1c, and the analysis pointed to an optimum near 3 sessions per week at 44% of one-rep max, 45 minutes per session, roughly 1,500 repetitions weekly, over 23 weeks.

   ⚠What it shows: Useful pointers rather than a prescription: results were pooled from just 10 trials with 633 mostly older adults, so the precise optimum figures carry wide uncertainty even though the overall direction, that lifting lowers HbA1c, is consistent.Systematic review · Front Physiol

   Full breakdown →Insulin sensitivity explained →One-Rep Max Calculator →Optimal exercise dose for resistance training to improve HbA1c levels in overweight and obese patients with type 2 diabetes: a systematic review of randomized controlled trials and a Bayesian network meta-analysis. Front Physiol 2026
3. Metabolic & GLP-1well supported · human dataAdded 26 August 2026

   How you're coached matters: behaviour-change plans added 3287 daily steps

   Across 62 trials in 8952 adults with cardiometabolic conditions, behaviour-change programmes added 3287 steps per day versus usual care, and multi-component interventions were the only design to improve every measure of physical activity. Multi-component approaches also reduced HbA1c by 0.24%.

   ⚠What it shows: Solid pooled evidence from 62 trials in 8952 adults with conditions like type 2 diabetes and heart disease, though the studies disagreed with each other in places and evidence quality varied. It compares how programmes are designed, not whether exercise itself works.Meta-analysis · BMC Med

   Full breakdown →Metabolic syndrome explained →Steps to Calories Calculator →Effectiveness of different intervention designs for improving physical activity in adults with cardiometabolic conditions over time: a systematic review and network meta-analysis of randomised controlled trials. BMC Med 2025
4. Metabolic & GLP-1well supported · human dataAdded 25 August 2026

   Semaglutide cuts major heart events by 19%, but many stop taking it

   Pooling four randomised trials in 27,617 people, semaglutide lowered the risk of major cardiovascular events by 19% versus placebo, with clear benefits for cardiovascular death and non-fatal heart attack. It did not significantly reduce non-fatal stroke or hospital admissions for heart failure or unstable angina, and people on the drug were more likely to stop treatment.

   ⚠What it shows: About as solid as pooled evidence gets for a newer drug: four trials where 27,617 people were assigned at random to semaglutide or placebo, and the trials agreed closely on the heart benefit. They disagreed sharply on how many people quit the drug, so treat that part as rough.Meta-analysis · BMC Cardiovasc Disord

   Full breakdown →GLP-1 explained →Heart Age Calculator →Cardiovascular benefits of semaglutide: a systematic review and meta-analysis of randomized controlled trials. BMC Cardiovasc Disord 2025
5. Metabolic & GLP-1well supported · human dataAdded 25 August 2026

   Tirzepatide sheds up to 11.8 kg in trials, and your gut pays the toll

   Across six randomised trials with 4036 participants, tirzepatide cut body weight versus placebo by 7.7 kg at the 5 mg dose and 11.8 kg at 15 mg, a 12.4% reduction at the top dose. Nausea, vomiting and diarrhoea were all markedly more common than on placebo.

   ⚠What it shows: Strong pooled evidence: six trials where 4036 people were given tirzepatide or placebo at random, running anywhere from 12 to 72 weeks. It says nothing about what happens to the weight once the injections stop.Meta-analysis · Int J Obes (Lond)

   Full breakdown →Energy balance explained →Efficacy and safety of the dual GIP and GLP-1 receptor agonist tirzepatide for weight loss: a meta-analysis of randomized controlled trials. Int J Obes (Lond) 2023
6. Metabolic & GLP-1well supported · human dataAdded 23 August 2026

   Fasting's cardiometabolic payoff is real, measurable and modest

   Pooled data from randomised trials show intermittent fasting reduced body weight by 1.78 kg, fat mass by 1.26 kg and waist circumference by 1.19 cm versus control diets, with small improvements in blood pressure, fasting insulin, insulin resistance, total cholesterol and triglycerides. LDL, HDL and long-term blood sugar did not change.

   ⚠What it shows: Believable but modest: results pooled from randomised trials up to October 2020 show small, consistent improvements across weight, waist, blood pressure and blood fats. The authors themselves say longer and better designed trials are needed before firm conclusions.Systematic review · Front Nutr

   Full breakdown →Metabolic syndrome explained →Metabolic Fitness Index →Effect of Epidemic Intermittent Fasting on Cardiometabolic Risk Factors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Front Nutr 2021
7. Metabolic & GLP-1preliminary · human dataAdded 23 August 2026

   Cardio plus weights ranks best for cooling inflammation in metabolic syndrome

   In a network meta-analysis of 28 randomised trials in people with metabolic syndrome, combined aerobic and resistance training produced the largest reduction in the inflammatory marker CRP, and that finding held up as robust. Apparent reductions in TNF-α and IL-6 were far less reliable.

   ⚠What it shows: Trust the CRP finding, be wary of the rest: pooled from 28 trials, the CRP result was rated moderate certainty with no sign that negative studies went missing. For TNF-α and IL-6 the studies disagreed wildly, and there were signs unfavourable results never got published.Review · J Investig Med

   Full breakdown →Metabolic syndrome explained →Heart Rate Zone Calculator →EXPRESS: Effects of Aerobic, Resistance, and Combined Exercise on Inflammatory Markers in Patients with Metabolic Syndrome: A Systematic Review and Network Meta-Analysis. J Investig Med 2026
8. Metabolic & GLP-1well supported · human dataAdded 23 August 2026

   Semaglutide outperforms its GLP-1 rivals, at a cost to the stomach

   In head-to-head trials in adults with type 2 diabetes, semaglutide lowered HbA1c by an extra 0.44% and body weight by an extra 2.53 kg compared with other GLP-1 drugs, but it also caused significantly more gastrointestinal side effects and more people stopping treatment.

   ⚠What it shows: Strong for what it measures: results pooled from 5 head-to-head trials in 3760 people with type 2 diabetes, so the comparison is direct rather than inferred. It tracked blood markers and weight rather than heart attacks or deaths, and the extra benefit came with more people quitting the drug.Meta-analysis · J Diabetes Complications

   Full breakdown →Metabolic syndrome explained →Effect of semaglutide versus other glucagon-like peptide-1 receptor agonists on cardio-metabolic risk factors in patients with type 2 diabetes: A systematic review and meta-analysis of head-to-head, phase 3, randomized controlled trials. J Diabetes Complications 2023
9. Metabolic & GLP-1preliminary · human dataAdded 23 August 2026

   Workplace wellness programmes barely dent men's waistlines

   Pooled across 11 randomised trials, workplace health programmes for men cut body weight by an average of 0.28 kg within 3 months and 1.38 kg beyond 3 months, changes that were not statistically significant despite improvements in snacking, sugary drink intake and physical activity.

   ⚠What it shows: Suggestive at best: results pooled from 11 trials in working men pointed the right way, but none of the weight changes reached statistical significance. Most trials were short, so nobody knows whether these programmes deliver over years.Meta-analysis · Health Educ Behav

   Full breakdown →Energy balance explained →Calorie Deficit Calculator →Workplace Health Promotion Programs Targeting Smoking, Nutrition, Physical Activity, and Obesity in Men: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Health Educ Behav 2024
10. Metabolic & GLP-1preliminary · human dataAdded 23 August 2026

    High-dose semaglutide shows a colorectal tumour signal in pooled trial data

    In pooled data from 68 randomised trials with 207 200 participants, only semaglutide was associated with a higher incidence of colorectal tumours, and only in its high-dose injectable form at 2.4 mg per week; other GLP-1 receptor agonists and all SGLT2 inhibitors showed no such association.

    ⚠What it shows: An early warning light, not a verdict: pooled data from 68 trials with 207 200 people can surface rare events, and the authors themselves call this a signal needing validation. People with obesity already carry a higher baseline colorectal risk, which complicates interpretation.Meta-analysis · Int J Surg

    Full breakdown →GLP-1 explained →The different colorectal tumor risk related to GLP-1 receptor agonists and SGLT2 inhibitors use: a network meta-analysis of 68 randomized controlled trials. Int J Surg 2026
11. Metabolic & GLP-1well supported · human dataAdded 23 August 2026

    A month of Ramadan fasting nudges cholesterol the right way, just barely

    Pooled results from 91 studies of 4431 healthy adults show a month of dawn-to-sunset fasting during Ramadan produced small favourable shifts in heart-risk markers, most clearly a rise in HDL cholesterol and a fall in LDL cholesterol. The authors describe any protection as short-term and transient.

    ⚠What it shows: A big evidence base but small effects: pooled from 91 studies of 4431 healthy adults across 23 countries. Most changes were slight, and the authors themselves call the protection short-term and transient, so nothing here shows the benefit outlasts the fasting month.Meta-analysis · Nutr Metab Cardiovasc Dis

    Full breakdown →Metabolic syndrome explained →Heart Age Calculator →Does four-week consecutive, dawn-to-sunset intermittent fasting during Ramadan affect cardiometabolic risk factors in healthy adults? A systematic review, meta-analysis, and meta-regression. Nutr Metab Cardiovasc Dis 2021
12. Metabolic & GLP-1well supported · human dataAdded 22 August 2026

    Next-generation GLP-1 drugs cut 4.16% of body weight, with vomiting the price

    In pooled results from 11 published and four unpublished randomised trials, the GLP-1 and glucagon dual agonists mazdutide and cotadutide cut body weight by 4.16% and HbA1c by 0.63% versus placebo in people with type 2 diabetes, obesity or both. Serious adverse events did not rise, but the odds of vomiting were 6.05 times higher.

    ⚠What it shows: A solid pooled picture: results combined from 11 published and four unpublished trials against placebo, so the benefits look real, though four of the datasets have not passed peer review and everyday side effects such as vomiting were far more common on the drugs.Meta-analysis · Endocrine

    Full breakdown →GLP-1 explained →Safety and efficacy of GLP-1 and glucagon receptor dual agonist for the treatment of type 2 diabetes and obesity: a systematic review and meta-analysis of randomized controlled trials. Endocrine 2024
13. Metabolic & GLP-1well supported · human dataAdded 22 August 2026

    Fasting Ramadan with type 2 diabetes? Medication choice shapes the risk of lows

    A sweep of 68 studies found that people with type 2 diabetes who fast during Ramadan have a lower risk of hypoglycaemic events on non-sulfonylurea medications than on sulfonylureas, with risk also shaped by diet, fasting length, sex, season, time since diagnosis and pre-fasting education.

    ⚠What it shows: Broad but not boiled down to one number: a sweep of 68 studies, 35 trials where people were assigned at random and 33 that followed people through the month, all in adults with type 2 diabetes. It maps who is most at risk rather than pooling a single figure, so exact risk sizes vary between studies.Systematic review · Front Endocrinol (Lausanne)

    Full breakdown →Impact of Ramadan Diurnal Intermittent Fasting on Hypoglycemic Events in Patients With Type 2 Diabetes: A Systematic Review of Randomized Controlled Trials and Observational Studies. Front Endocrinol (Lausanne) 2021
14. Metabolic & GLP-1preliminary · human dataAdded 22 August 2026

    An earlier eating window edges ahead for blood sugar control

    Pooling 39 randomised trials in 3,236 adults with cardiometabolic risk factors, an early time-restricted eating window reduced fasting blood glucose by 3.64 mg/dL and insulin resistance versus control, and early windows, especially combined with exercise, consistently ranked best across outcomes.

    ⚠What it shows: Promising but not settled: results pooled from 39 trials in 3,236 adults with cardiometabolic risk factors. The certainty of the evidence ranged from very low to moderate, and the rankings rest on a limited number of trials, so they could shift as more arrive.Systematic review · Front Nutr

    Full breakdown →Insulin sensitivity explained →Early, midday, and late time-restricted eating impact on anthropometry and cardiometabolic health: a network meta-analysis of RCTs. Front Nutr 2026
15. Metabolic & GLP-1preliminary · human dataAdded 22 August 2026

    Gastric bypass keeps far more weight off than diet and drugs years later

    In a Cochrane network meta-analysis of 18 studies with 15,282 adults with obesity and type 2 diabetes, Roux-en-Y gastric bypass was linked to 16.95% greater long-term weight loss than lifestyle and medical treatment, and it may also lower HbA1c and make partial diabetes remission more likely. For most other outcomes, including complete remission, serious adverse events and mortality, the evidence remained very uncertain.

    ⚠What it shows: Cochrane rigour applied to thin raw material: the weight-loss comparison rests on 8 trials with just 491 people, and the reviewers themselves rate most findings uncertain or very uncertain because the trials were small and serious events rare. The direction favours surgery; the size and safety picture are still genuinely open.Meta-analysis · Cochrane Database Syst Rev

    Full breakdown →Insulin sensitivity explained →Metabolic and bariatric surgery in adults with obesity and diabetes mellitus: a network meta-analysis. Cochrane Database Syst Rev 2026
16. Metabolic & GLP-1well supported · human dataAdded 22 August 2026

    Diabetes drags down fitness, but staying active closes part of the gap

    A meta-analysis of 68 studies found cardiorespiratory fitness is markedly lower in people with type 1 and type 2 diabetes than in people without, with the larger gap in type 2. High physical activity levels partially closed the gap, while sedentary lifestyles and diabetes complications were linked to a wider one.

    ⚠What it shows: A robust pattern, but with a limit: the 68 pooled studies compared groups of people rather than testing an intervention, so this cannot prove diabetes causes the fitness gap or that activity alone would close it. The links to blood sugar control and body weight are associations, not demonstrated mechanisms.Meta-analysis · Med Sci Sports Exerc

    Full breakdown →VO₂max explained →VO2max Calculator →Cardiorespiratory Fitness Is Impaired in Type 1 and Type 2 Diabetes: A Systematic Review, Meta-Analysis, and Meta-Regression. Med Sci Sports Exerc 2024
17. Metabolic & GLP-1well supported · human dataAdded 22 August 2026

    Belly fat shrinks with cardio or weights alike, and most when you do both

    Pooling 43 randomised trials with 3552 adults, aerobic training, resistance training and combined training all reduced subcutaneous abdominal fat, with combined training showing the largest reduction. Head to head, aerobic and resistance training did not differ significantly from each other.

    ⚠What it shows: A broad sweep of the evidence: results pooled from 43 trials in 3552 adults, most of them women, all point to exercise trimming the fat layer under the belly skin. The trials varied enough that outliers had to be removed, and the search only ran to late 2018, so newer trials are not counted.Meta-analysis · Adv Nutr

    Full breakdown →Energy balance explained →Body Fat Calculator →The Effect of Aerobic and Resistance Training and Combined Exercise Modalities on Subcutaneous Abdominal Fat: A Systematic Review and Meta-analysis of Randomized Clinical Trials. Adv Nutr 2021
18. Metabolic & GLP-1well supported · human dataAdded 21 August 2026

    A month of daily fasting barely shifts blood sugar or insulin in healthy people

    Across 72 studies of 3134 healthy people in 22 countries, a month of Ramadan daytime fasting produced only a tiny drop in fasting glucose and no meaningful change in insulin, insulin resistance, leptin or adiponectin.

    ⚠What it shows: Reassuring rather than revolutionary: results pooled from 72 studies of 3134 healthy non-athletes across 22 countries. Ramadan fasting bans food and drink in daylight hours only, so the findings may not transfer neatly to other intermittent fasting styles.Meta-analysis · Diabetes Res Clin Pract

    Full breakdown →Insulin sensitivity explained →A systematic review, meta-analysis, and meta-regression of the impact of diurnal intermittent fasting during Ramadan on glucometabolic markers in healthy subjects. Diabetes Res Clin Pract 2020
19. Metabolic & GLP-1well supported · human dataAdded 21 August 2026

    Cardio while dieting cools the inflammation a diet alone leaves behind

    In a network meta-analysis of 24 randomised trials with 1,694 people with overweight or obesity, adding aerobic exercise to calorie restriction lowered inflammatory markers including CRP, hs-CRP, TNF-α and IL-6 more than dieting alone. No exercise type produced a significant extra improvement in insulin resistance beyond the diet itself.

    ⚠What it shows: Reasonably solid on the headline result: findings pooled from 24 trials in 1,694 people with overweight or obesity, though several comparisons rested on only a few studies, so the ranking of exercise types is far from settled.Systematic review · Front Nutr

    Full breakdown →Energy balance explained →Calorie Deficit Calculator →Comparative efficacy of exercise modalities added to energy restriction on inflammatory markers in obesity: a systematic review and network meta-analysis. Front Nutr 2026
20. Metabolic & GLP-1well supported · human dataAdded 21 August 2026

    HIIT edges out other exercise for blood sugar in type 2 diabetes

    In a network meta-analysis of 158 trials with 17,059 people with type 2 diabetes, every form of exercise lowered HbA1c, with HIIT topping the ranking at a 0.61% reduction and even simple activity advice cutting 0.35%.

    ⚠What it shows: About as solid as exercise evidence gets: results pooled from 158 trials in 17,059 people with type 2 diabetes, all lasting at least 12 weeks. The rankings between exercise types rest partly on indirect comparisons, so the gap between HIIT and the rest is real but not ironclad.Meta-analysis · Diabetes Res Clin Pract

    Full breakdown →HIIT explained →Heart Rate Zone Calculator →Effects of exercise training and physical activity advice on HbA1c in people with type 2 diabetes: A network meta-analysis of randomized controlled trials. Diabetes Res Clin Pract 2025
21. Metabolic & GLP-1preliminary · human dataAdded 20 August 2026

    Tirzepatide edges out semaglutide in a cross-trial weight loss comparison

    In an indirect comparison of matched Phase 3 trials, tirzepatide 10 mg and 15 mg produced 4% and 5.4% additional weight loss and a 0.4% larger HbA1c reduction than semaglutide 2.4 mg, with fewer gastrointestinal side effects; the two drugs have never been compared head to head.

    ⚠What it shows: Treat this as a strong hint, not a verdict: the two drugs have never been tested in the same trial, so researchers lined up results from separate large trials instead, a method that can mislead. Two of the authors have received speaker fees from the makers of both drugs.Systematic review · Diabetes Metab Syndr

    Full breakdown →GLP-1 explained →Comparative efficacy and safety of semaglutide 2.4 mg and tirzepatide 5-15 mg in obesity with or without type 2 diabetes: A systematic review of Phase 3 clinical trials. Diabetes Metab Syndr 2025
22. Metabolic & GLP-1well supported · human dataAdded 20 August 2026

    Two weeks of plant-based eating can shift insulin resistance

    Plant-based diets followed for at least 14 days improved HOMA-IR, a marker of insulin resistance, and lowered fasting insulin in adults with overweight or obesity, across pooled randomised trials. Single studies in people with prediabetes and type 2 diabetes found no such differences.

    ⚠What it shows: Encouraging but short-term: results pooled from eight trials with 716 adults, and the clear gains were confined to people with overweight or obesity. Some diets lasted only a fortnight, so nobody knows whether the improvements persist over months or years.Meta-analysis · Nutrients

    Full breakdown →Insulin sensitivity explained →Metabolic Fitness Index →Effects of Plant-Based Diets on Markers of Insulin Sensitivity: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Nutrients 2024
23. Metabolic & GLP-1preliminary · human dataAdded 19 August 2026

    CagriSema beats semaglutide at its own weight-loss game

    In pooled data from seven randomised trials with 8,069 overweight or obese participants, the combination drug CagriSema produced 13.99 kg more weight loss than placebo, 9.24 kg more than cagrilintide alone and 7.58 kg more than semaglutide alone, with mainly gastrointestinal side effects and no increase in serious adverse events.

    ⚠What it shows: Strong short-term evidence: results pooled from seven trials in 8,069 overweight or obese adults, showing consistent extra weight loss beyond either drug alone. Long-term safety and whether the loss lasts are still open questions, and the blood sugar results were mixed between trials.Review · Naunyn Schmiedebergs Arch Pharmacol

    Full breakdown →GLP-1 explained →Calorie Deficit Calculator →Maximizing weight loss with cagrisema: a systematic review and GRADE-assessed meta-analysis of randomized controlled trials. Naunyn Schmiedebergs Arch Pharmacol 2026
24. Metabolic & GLP-1well supported · human dataAdded 19 August 2026

    Exercise fixes metabolic markers before it touches inflammation

    Pooling 35 randomised trials in 2752 adults with overweight or obesity, exercise training raised adiponectin and maximal oxygen uptake by 5.26 mL/kg/min, and lowered fasting insulin, fasting glucose, insulin resistance and triglycerides, while inflammation markers such as CRP, IL-6 and TNF-α did not change significantly.

    ⚠What it shows: Strong on the metabolic wins, weaker on inflammation: results pooled from 35 trials in 2752 adults with overweight or obesity. The classic inflammation markers did not move, and the authors call for longer studies to confirm the picture.Meta-analysis · J Sports Med Phys Fitness

    Full breakdown →Insulin sensitivity explained →VO2max Calculator →Effects of exercise training on inflammatory and cardiometabolic health markers in overweight and obese adults: a systematic review and meta-analysis of randomized controlled trials. J Sports Med Phys Fitness 2023

Back to the full archive · this week’s studies